Original article
Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study
Comparación de las características clínicas basales entre personas con diabetes tipo 2 en terapia de segunda línea previamente agregada con dapagliflozina u otro fármaco hipoglucemiante oral. Estudio AGORA
Vicente Pallarés-Carrataláa,1,
, Antonio Ruiz-Garcíab,c,1, Adalberto Serrano-Cumplidod, Antonio Segura Fragosoe, Verónica Fernández-Pascualf, Beatriz Sánchez-Sánchezf, María Inmaculada Cervera-Pérezg, Francisco Javier Alonso-Morenoh, Ezequiel Arranz-Martínezi, Alfonso Barquilla-Garcíaj, Daniel Rey-Aldanak, José Polo Garcíal, Sergio Cinza-Sanjurjom,n, on behalf of the Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation
Corresponding author
a Department of Medicine, Jaume I University, Castellon, Spain
b Specialist in Family and Community Medicine, Pinto University Health Center, Lipids and Cardiovascular Prevention Unit, Pinto, Madrid, Spain
c Department of Medicine, European University of Madrid, Villaviciosa de Odón, Madrid, Spain
d Specialist in Family and Community Medicine, Getxo, Vizcaya, Spain
e Epidemiology Unit, Semergen Research Agency, Madrid, Spain
f Investigation Unit, SEMERGEN Foundation, Madrid, Spain
g Specialist in Family and Community Medicine, Tendetes Health Center, Valencia, Spain
h Specialist in Family and Community Medicine, Sillería Health Center, Toledo, Spain
i Especialista en Medicina Familiar y Comunitaria, San Blas Health Center, Parla, Madrid, Spain
j Specialist in Family and Community Medicine, Trujillo Health Center, Cáceres, Spain
k Specialist in Family and Community Medicine, A Estrada Health Center, Pontevedra, Spain
l Specialist in Family and Community Medicine, Casar de Cáceres Health Center, Cáceres, Spain
m Milladoiro Health Centre, Health Area of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain
n Networking Biomedical Research, Centre-Cardiovascular Diseases (CIBERCV), Santiago de Compostela, Spain
Ver más